Symbols

VRCA

Verrica·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 0

Revenue Beats Expectation

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About VRCA

Verrica Pharmaceuticals Inc.

A dermatology therapeutics company developing medications for skin diseases requiring medical interventions

Industry

Pharmaceutical

Established Date

07/03/2013

Listing Date

06/15/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.verrica.com

Security Type

Common stock

Office address

44 West Gay Street, Suite 400, West Chester, PA 19380

Business

Introduction

Verrica Pharmaceuticals Inc., was incorporated under the laws of the State of Delaware on July 3, 2013. The Company is a company that develops and commercializes clinically administered therapeutic drugs for skin diseases, including skin cancer. Its commercial product YCANTH has been approved for the treatment of molluscum contagiosum, and the R&D pipeline also includes drug candidates for warts vulgaris and basal cell carcinoma.

Company Financials

EPS

VRCA has released its 2025 Q4 earnings. EPS was reported at -0.57, versus the expected -0.06, missing expectations. The chart below visualizes how VRCA has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

VRCA has released its 2025 Q4 earnings report, with revenue of 5.09M, reflecting a YoY change of 1380.23%, and net profit of -8.07M, showing a YoY change of 50.17%. The Sankey diagram below clearly presents VRCA's revenue sources and cost distribution.